24.54
前日終値:
$23.85
開ける:
$24.1
24時間の取引高:
6.48M
Relative Volume:
1.11
時価総額:
$12.60B
収益:
$11.89B
当期純損益:
$-560.00M
株価収益率:
-22.31
EPS:
-1.1
ネットキャッシュフロー:
$191.00M
1週間 パフォーマンス:
+1.49%
1か月 パフォーマンス:
-10.80%
6か月 パフォーマンス:
-27.44%
1年 パフォーマンス:
-32.75%
Baxter International Inc Stock (BAX) Company Profile
名前
Baxter International Inc
セクター
電話
(224) 948-2000
住所
ONE BAXTER PARKWAY, DEERFIELD, IL
BAX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
BAX
Baxter International Inc
|
24.54 | 12.13B | 11.89B | -560.00M | 191.00M | -1.10 |
![]()
ISRG
Intuitive Surgical Inc
|
476.16 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
![]()
BDX
Becton Dickinson Co
|
199.66 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
![]()
ALC
Alcon Inc
|
82.02 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
![]()
RMD
Resmed Inc
|
293.73 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
![]()
WST
West Pharmaceutical Services Inc
|
247.85 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-08-04 | ダウングレード | Stifel | Buy → Hold |
2025-08-01 | ダウングレード | Goldman | Buy → Neutral |
2025-02-26 | 再開されました | Goldman | Buy |
2025-02-24 | アップグレード | Argus | Hold → Buy |
2025-02-20 | 再開されました | Barclays | Overweight |
2024-07-15 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2024-05-30 | 開始されました | Goldman | Neutral |
2024-05-10 | ダウングレード | TD Cowen | Buy → Hold |
2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
2023-03-29 | 開始されました | UBS | Neutral |
2023-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-01-05 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2023-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
2022-12-19 | ダウングレード | JP Morgan | Overweight → Neutral |
2022-12-15 | ダウングレード | Deutsche Bank | Buy → Hold |
2022-12-12 | ダウングレード | Citigroup | Buy → Neutral |
2022-10-18 | 開始されました | Barclays | Overweight |
2022-10-12 | 開始されました | Jefferies | Hold |
2022-06-24 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2022-04-04 | ダウングレード | Goldman | Neutral → Sell |
2022-03-02 | 再開されました | BofA Securities | Buy |
2022-02-18 | 繰り返されました | KeyBanc Capital Markets | Overweight |
2022-02-18 | 繰り返されました | Morgan Stanley | Overweight |
2022-02-18 | 繰り返されました | Raymond James | Outperform |
2022-02-18 | 繰り返されました | Stifel | Buy |
2022-02-18 | 繰り返されました | UBS | Neutral |
2022-02-18 | 繰り返されました | Wells Fargo | Overweight |
2022-02-11 | 開始されました | Goldman | Neutral |
2022-01-07 | 再開されました | Citigroup | Buy |
2022-01-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2021-09-13 | アップグレード | Cowen | Market Perform → Outperform |
2021-09-03 | アップグレード | Barclays | Equal Weight → Overweight |
2021-05-25 | 開始されました | Barclays | Equal Weight |
2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
2021-01-06 | ダウングレード | UBS | Buy → Neutral |
2020-12-15 | ダウングレード | Goldman | Buy → Neutral |
2020-10-01 | アップグレード | Citigroup | Neutral → Buy |
2020-09-04 | ダウングレード | Argus | Buy → Hold |
2020-06-24 | 開始されました | Oppenheimer | Outperform |
2020-03-19 | アップグレード | Stifel | Hold → Buy |
2020-03-18 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
2020-03-05 | 開始されました | Citigroup | Neutral |
2020-02-13 | 開始されました | Goldman | Buy |
2020-01-02 | アップグレード | Evercore ISI | In-line → Outperform |
2019-12-17 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2019-06-26 | 開始されました | KeyBanc Capital Markets | Sector Weight |
2019-04-08 | ダウングレード | Evercore ISI | Outperform → In-line |
2019-01-02 | アップグレード | Citigroup | Neutral → Buy |
2019-01-02 | アップグレード | Morgan Stanley | Underweight → Overweight |
2018-11-02 | アップグレード | Argus | Hold → Buy |
2018-10-16 | 開始されました | Barclays | Underweight |
2018-05-17 | 再開されました | Piper Jaffray | Overweight |
2018-02-06 | 繰り返されました | Citigroup | Neutral |
2018-01-03 | 開始されました | Evercore ISI | Outperform |
2018-01-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
すべてを表示
Baxter International Inc (BAX) 最新ニュース
How Hurricanes, Fires and Floods Put Drugs and Medical Supplies at Risk - Bloomberg.com
Options Data Show Bullish Bias in Baxter International Inc.Weekly Stock Analysis & Weekly Top Stock Performers List - beatles.ru
Stock Analysis | Baxter International OutlookMixed Signals as Technical and Analyst Views Diverge - AInvest
Baxter International (NYSE:BAX) Stock Acquired Rep. Lisa C. McClain - MarketBeat
Ligand to Participate in September Investor Conferences - GlobeNewswire Inc.
How Baxter International Inc. (BAX) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Russell Investments Group Ltd. Sells 69,685 Shares of Baxter International Inc. $BAX - MarketBeat
Baxter International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Earnings call transcript: Baxter Q2 2025 misses EPS forecast, stock drops - Investing.com Canada
Surgeons Convene at Vienna Symposium to Experience Baxter's HEMOPATCH Sealing Hemostat - Financial Times
Forsta AP Fonden Sells 188,100 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Precision Trading with Baxter International Inc. (BAX) Risk Zones - news.stocktradersdaily.com
Baxter's Novum IQ Infusion Pump Safety Crisis: Implications for Medical Device Investors - AInvest
Is There An Opportunity With Baxter International Inc.'s (NYSE:BAX) 33% Undervaluation? - au.finance.yahoo.com
Trend Dashboard Flags Baxter International Inc. As Potential Swing TradeJuly 2025 Weekly Recap & Real-Time Price Movement Reports - beatles.ru
Baxter downgraded to Hold at Stifel on weak Q2 report - MSN
Baxter International (BAX) Is Up 7.2% After Profitable Q2 and Raised Sales GuidanceWhat's Changed - simplywall.st
Here’s Why You Should Consider Selling Your Baxter (BAX) Shares - Insider Monkey
Ascites Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company - The Globe and Mail
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - Yahoo Finance
Baxter to split into two companies - The Covington News
Morgan Stanley Keeps Sell Rating on Baxter International with $19 Target - AInvest
Baxter Launches HEMOPATCH Sealing Hemostat in New Zealand, a Room-Temperature Collagen Pad Approved for Hemostasis and Sealing - Fierce Healthcare
Baxter International (BAX) Is Up 7.9% After Reversing Losses and Reaffirming 2025 Sales Growth Outlook - simplywall.st
UBS Group Cuts Baxter International (NYSE:BAX) Price Target to $24.00 - MarketBeat
Baxter International's GF Score Indicates Potential for Underperformance - AInvest
FDA's IV Shortage Resolution Lifts Baxter's Volume to 394th Rank as Stock Rises 0.64% - AInvest
Barclays Issues Pessimistic Forecast for Baxter International (NYSE:BAX) Stock Price - MarketBeat
Baxter International's (BAX) Hold Rating Reiterated at Stifel Nicolaus - MarketBeat
Arkadios Wealth Advisors Acquires Shares of 17,245 Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International Inc. shares rise 1.98% intraday after ATS Corporation reported Q1 revenue growth and provided Q2 revenue guidance. - AInvest
Baxter International Inc. (NYSE:BAX) Shares Bought by Raiffeisen Bank International AG - MarketBeat
Are Wall Street Analysts Bullish on Baxter International Stock? - MSN
LSV Asset Management Sells 391,800 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International 2025 Q2 Earnings Strong Turnaround as Net Income Surges 129% - AInvest
Baxter International (BAX) Falls to New Low on Disappointing Growth Forecast - MSN
Baxter International Inc. (BAX): A Bull Case Theory - Insider Monkey
Wall Street Zen Downgrades Baxter International (NYSE:BAX) to Hold - MarketBeat
Baxter International Surges 1.78% on $330M Volume Ranking 363rd as Tactical Strategy Outperforms Benchmark by 137.53 Pts - AInvest
Baxter stock rises on earnings beat, guidance raise - MSN
Baxter International (NYSE:BAX) Updates FY 2025 Earnings Guidance - MarketBeat
Baxter International (NYSE:BAX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Stifel Downgrades Baxter International (BAX) - MSN
Baxter slashes its profit forecast after disappointing quarter - Medical Buyer
Barclays Lowers Price Target on Baxter International to $36 From $41, Maintains Overweight Rating - MarketScreener
Baxter International Inc (BAX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):